302 EAST PETTIGREW STREET, DURHAM, NC
Market cap: $49.8M (2/09/2026)
Price: $3.76
Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy
Precision BioSciences Prioritizes PBGENE-HBV and PBGENE-DMD Programs for 2026
Precision BioSciences Enters Underwriting Agreement for Stock Offering
Precision BioSciences Presents Phase 1 PBGENE-HBV Data Showing Antiviral Activity
Reports Third Quarter 2025 Financial Results and Provides Business Update
Changes in Board, Management or Compensation
Earnings Release
Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
Q3
Q2
Q1
FY 2024
FY 2023
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus